iRhythm Technologies announced it has received another FDA 510(k) clearance for its ZEUS (Zio ECG Utilization Software) System that works with a wearable to monitor patients with atrial fibrillation, an irregular heart rhythm.
Developed in partnership with Alphabet life science subsidiary Verily, the ZEUS System is a platform that works with the Zio Watch to detect AFib, characterize the amount...
iRhythm Technologies, maker of the Zio XT and Zio AT adhesive heart monitors, announced first quarter financials boasting higher revenue and an improved gross margin during an earnings call for investors earlier this week. These promising numbers were paired with a net loss nearly double what was reported last year during the same quarter, although these were waved off by executives as the result...
iRhythm Technologies, maker of the ZIO patch peel-and-stick heart monitor, announced on its second quarter earnings call that it increased its revenue 52 percent year over year (for a total revenue of $23.9 million) and achieved its first cash flow break-even quarter.
CEO Kevin King also shared a rough timetable for the company's forthcoming Zio AT product, which received FDA clearance in June....
iRhythm Zio is in many ways a poster child for a connected health company. The company, which makes a peel-and-stick patch for mobile ECG recording, is one of the few wearable medical device companies to go public, and few digital technologies have as soundly improved on the status quo as Zio has on the Holter monitor, a long-term legacy monitoring technology.
There's only one problem with...
iRhythm, the wearable heart monitor company that announced its intention to IPO last month, went public today and increased its share price and number of shares on offer, raising the value of its IPO from an expected $86 million to $107 million.
The company is offering 6,294,118 shares of its common stock at a public offering price of $17.00 per share, before underwriting discounts. Underwriters...
